Category - M&As and partnerships

Leading Biopharmaceutical Companies Select Invitae to Develop Standardized Panel to Detect Molecular Residual Disease (MRD) in Patients with Acute Myeloid Leukemia (AML)

Project aims to standardize MRD data generation, assessment and accelerate AML clinical trial programs bringing novel therapies to patients in need faster SAN FRANCISCO, Jan. 14, 2021 /PRNewswire/ — Invitae...read more

Personal Genome Diagnostics and QIAGEN Collaborate to Offer Integrated Genomic Testing and Interpretation Support

Partnership to Accelerate Adoption of Next-Generation Sequencing (NGS) in Clinical Decision-Making Comprehensive Pan-Cancer Tumor Profiling Assays can be Combined with Clinical Informatics Platform with Potential to...read more

Pacific Biosciences and Invitae to Develop Ultra-High-Throughput Clinical Whole Genome Sequencing Platform

New platform expected to make whole genome sequencing significantly more affordable and accessible for use in mainstream medical care MENLO PARK, Calif., Jan. 13, 2021 (GLOBE NEWSWIRE) — Pacific Biosciences of...read more

Broad Institute and Verily partner with Microsoft to accelerate the next generation of the Terra platform for health and life science research

QIAGEN Announces Global Distribution Agreement for the COSMIC Database from the Wellcome Sanger Institute

Exclusive sales, marketing, support and distribution by QIAGEN Including over 71 million cancer mutations, the COSMIC Database joins QIAGENs’ portfolio for cancer genomic analysis and interpretation Agreement effective...read more